Oligomerix launches phase 1a trial for tau self-association inhibitor for Alzheimer’s

Dosing has begun in participants enrolled in a phase 1a clinical trial of OLX-07010, an oral small molecule inhibitor of tau self-association for Alzheimer’s disease, manufacturer Oligomerix announced in a press release.

“With its targeted safety and efficacy profile, OLX-07010 has the potential to fill a significant void in treatment options for patients suffering from devastating neurodegenerative diseases,” James Moe, PhD, MBA, CEO and head of discovery and strategy at Oligomerix, said in the release.

The phase 1a study will assess the safety and tolerability of OLX-07010 in single-ascending and multiple-ascending doses in healthy volunteers and later in a cohort of older individuals. The investigational therapy has already demonstrated efficacy in preclinical trials, the company stated.

“It is critical the neuroscience community continue its efforts to develop better treatment strategies for serious neurological disorders,” William Erhardt, MD, president and head of development and operations at Oligomerix, said in the release. “Over the last 2 years, Oligomerix has made significant progress in demonstrating how inhibiting tau self-association can have remarkable effects in preclinical models of AD and neurodegenerative conditions.

“With the start of this phase 1a study, we look forward to working closely with our stakeholders, from patients to caregivers to regulatory officials, as we characterize the clinical profile of OLX-07010.”